Obiamiwe Umeh

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

Florian Wagenlehner, Obiamiwe Umeh, Judith N. Steenbergen et al. · The Lancet · 2015 · 382 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a pooled analysis of Phase 3 clinical trials

Myra W. Popejoy, David L. Paterson, Daniel Cloutier et al. · Journal of Antimicrobial Chemotherapy · 2016 · 123 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

Gurudatt Chandorkar, Jennifer A. Huntington, Mark H. Gotfried et al. · Journal of Antimicrobial Chemotherapy · 2012 · 119 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study

Christopher Lucasti, Abel Jasovich, Obiamiwe Umeh et al. · Clinical Therapeutics · 2008 · 111 citations

Pharmacy, Infectious Diseases, Pharmacokinetics +9

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Jennifer A. Huntington, George Sakoulas, Obiamiwe Umeh et al. · Journal of Antimicrobial Chemotherapy · 2016 · 59 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +15